Increasing the Effectiveness of Periodontal Pockets Treatment
One of the most widespread pathologies globally Periodontitis affects 50–60% of the adult population worldwide.1 This chronic infectious condition has been linked to other serious illnesses, such as diabetes and heart disease.2
As this is a chronic disease, patients can get frustrated with the time and financial effort needed3 in the process of dealing with it. This can often lead to patients leaving practices in order to find treatment elsewhere.
Since the 1960s, scaling and root planning (SRP) has proven its success as the first non-surgical method for treating periodontitis. However, it has certain limitations – in particular in its weakness in reaching deeper pockets.4 Clinical studies have shown that reinforcing SRP with antibiotic medication can improve treatment outcomes significantly as this helps combat mechanically unreachable areas.
Up to now systemic antibiotics have been the norm, as today 7 to 11% of antibiotics consumed are prescribed by dentists.5
Yet recent studies have shown that systemic antibiotics may have side effects6 as well as increased risk of causing bacterial resistance.7
Gelcide solves the problems posed by systemic antibiotics by offering complete on-site treatment, eliminating side effects and not contributing to an increase in bacterial resistance.
What is Gelcide? What differentiates Gelcide from other treatments?
Gelcide consists of a patented solution of piperacillin and tazobactam paired with a carrier that effectively dispenses the potent active formula right to the bottom of the dental pocket or the wound. The local-delivery application minimizes some of the problems of systemic antibiotics, such as side effects and increased bacterial resistance.
Because it is applied directly as a liquid to the affected area, Gelcide is particularly suitable for preventing damage to the surrounding bone. Its unique formula allows it to rapidly penetrate into the pocket and subsequently gelify inside, while, on the surface, it creates a strong external film that virtually seals the wound. These capabilities allow for easy application while ensuring that the active ingredients are retained at the infection site.
Current SRP treatments are rendered less effective because of poor patient compliance. They place the burden of treatment on patients themselves, expecting them to self-administer antibiotics up three times a day off site. Gelcide allows the practitioner full control of the treatment process, and as a result increases the certainty of treatment outcomes.
Gelcide’s exclusive formula is slowly released at effective concentrations for up to 8–10 days. The film is permeable but insoluble to fluids – protecting the pocket from further oral-bacteria exposure, subsequent irritation and infection.
This patented solution offers you an effective way of complementing standard SRP treatment. It will improve success rates, help prevent early body reabsorption and potential displacements – resulting in increased therapy compliance and more satisfied patients.
Ease of Application
- Fluid mix that penetrates deep into the dental pocket.
- Once applied, Gelcide ‘seals’ the pocket, solidifying as a gel after contact with fluids, thereby remaining in the pocket and acting as a film when making contact with air at the gingival level.
- No need for additional injection devices: all elements are included.
- No need to worry about patient compliance: all work can be carried out on site
Improved Effectiveness over Time
- Highly effective against a broad range of gram+ and gram- bacteria through antibiotic activity of piperacillin. Beta lactamase-induced bacterial resistance is prevented through coadministration of tazobactam.13
- Biodegradable and anti-microbial active for 7-10 days.
- Once opened, remains active for 4 weeks.
- No side effects due to 100-fold higher levels of concentration of active agent in subgingival site compared to systemic therapy.
- Slow-release mechanism and complete on-site treatment eliminate need for patients to follow up treatment off site.
- Unique film means patients do not need to adapt eating or drinking habits throughout duration of treatment.
Treatment and Practice Benefits
- Increased treatment compliance as doctor has higher control of the therapy.
- Dentist builds trust and loyalty by offering most up-do-date treatments that mean far less intrusion in patient’s day-to-day life.
- Incremental revenue with low incremental workload.
Thanks to easy application and rapid gelation and film creation, once Gelcide is injected into the dental pocket, the necessary quantity of active ingredient is secured.
Days 2 – 10
Patented technology retains the gel in the pocket. The slow-release mechanism of piperacillin-tazobactam ensures sustained availability of local treatment over a period of 7-10 days.
Days 10 – 12
After 10-12 days the gel has completely dissipated, and treatment has been completed, eliminating the need for gel removal or any follow-up, with the pocket showing significant improvement.
Gelcide offers you an effective way to combat biofilm and bacterial infections by:
Complementing your mechanical debridement in the deep periodontal pockets; Ensuring wound healing in sutures; and Limiting the risk of infection in post-extraction areas.
Benefits of locally delivered antibiotics is supported by strong scientific evidence9
Securing patient compliance
Only 60% of patients complete treatments that use systemic antibiotics.10
Offering patients more choices
A modern medical approach that improves retention rates and attracts new patients because of reduction in patient stress and better treatment outcomes.
Safe attainment of MIC levels
Use of local treatment in the affected area means patient’s body avoids any risks of reaching toxic antibiotic levels.11
Locally administered treatments
Gelcide is administered at site of infection, resulting in higher success rates than use of solely systemic antibiotics.12
No side effects
Side effects eliminated because of local application at site of infection.
2. American Academy of Periodontology, www.perio.org
3. Stenman J, Hallberg U et al. Patients’ attitudes towards oral health and experiences of periodontal treatment: a qualitative interview study. Oral Health Prev Dent. 2009; 7(4): 393–401
4. Collins F, Veis R. Periodontal treatment: the delivery and role of locally applied therapeutics.
5. Sweeney LC, et al. Antibiotic resistance in general dental practice – a cause for concern, J. Antimicrob Chemother. 2004; 53: 567–76
6. Elseviers M et al. Prevalence and management of antibiotic associated diarrhea in general hospitals. BMC Infectious Diseases. 2015; 15: 129
7. Rodrigues RM, Goncalves C et al. Antibiotic resistance profile of the subgingival microbiota following systemic or local tetracycline therapy. J Clin Periodontol. 2004; 31(6): 420–7
8. Laurestein M et al. Clinical and microbiological results following nonsurgical periodontal therapy with or without local administration of piperacillin/tazobactam. Clin Oral Invest. 2013; 1645–60
9. Lindhe J, et al. Clinical Periodontology and Implant Dentistry. 4th edn. Blackwell, Oxford: 479–81
10. Loesche WJ et al. Metronidazole in periodontitis (IV). The effect on patient compliance on treatment parameters. J Clin Periodontol. 1993 Feb; 20(2): 96–104
11. Wu H et al. Strategies for combating bacterial biofilm infections. International Journal of Oral Sciences. 2015; 7: 1–7
12. Engesaeter LB et al. Antibiotic prophylaxis in total hip arthroplasty: effects of antibiotic prophylaxis systemically and in bone cement on the revision rate of 22,170 primary hip replacements followed 0-14 years in the Norwegian Arthroplasty Register. Acta Orthop Scand. 2003; 74(6): 644–5
13. Rabbani GM et al. The effectiveness of subgingival scaling and root planning in calculus removal. J Periodontol 1981; 52: 119–23